Geode Capital Management
ANTX icon

Geode Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Geode Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.64M Sell
684,122
-13,684
-2% -$72.5K ﹤0.01% 3001
2026
Q2 		$3.38M Buy
697,806
+411,259
+144% +$1.77M ﹤0.01% 3064
2026
Q1 		$981K Buy
286,547
+34,672
+14% +$71.6K ﹤0.01% 3357
2025
Q4 		$287K Buy
251,875
+2,524
+1% +$2.95K ﹤0.01% 3791
2025
Q3 		$317K Hold
249,351
– – ﹤0.01% 3777
2025
Q2 		$264K Sell
249,351
-4,572
-2% -$5.45K ﹤0.01% 3779
2025
Q1 		$345K Buy
253,923
+26,127
+11% +$32.9K ﹤0.01% 3673
2024
Q4 		$314K Buy
227,796
+7,634
+3% +$9.26K ﹤0.01% 3747
2024
Q3 		$236K Buy
220,162
+39,239
+22% +$68.1K ﹤0.01% 3854
2024
Q2 		$389K Buy
180,923
+1,553
+0.9% +$3.7K ﹤0.01% 3664
2024
Q1 		$583K Buy
179,370
+747
+0.4% +$8.13K ﹤0.01% 3551
2023
Q4 		$3.66M Buy
178,623
+88,932
+99% +$1.49M ﹤0.01% 2857
2023
Q3 		$1.44M Buy
89,691
+36,729
+69% +$416K ﹤0.01% 3186
2023
Q2 		$450K Sell
52,962
-91,985
-63% -$661K ﹤0.01% 3684
2023
Q1 		$1.43M Buy
144,947
+21,862
+18% +$243K ﹤0.01% 3174
2022
Q4 		$1.17M Buy
123,085
+39,794
+48% +$533K ﹤0.01% 3279
2022
Q3 		$1.45M Buy
83,291
+6,824
+9% +$79.6K ﹤0.01% 3210
2022
Q2 		$592K Buy
+76,467
New +$1.01M ﹤0.01% 3672

Other funds holding ANTX

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Geode Capital Management's ANTX Position: Q3 2026 in Review

Geode Capital Management reduced its AN2 Therapeutics (ANTX) stake by 2% in Q3 2026, selling an estimated $72.5K and leaving 684,122 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3001.

Geode Capital Management first reported a position in ANTX in Q2 2022 and has held it in 18 quarters since. The position peaked at $3.66M in Q4 2023. 51 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • Geode Capital Management held 684,122 shares of AN2 Therapeutics worth $3.64M as of Q3 2026.
  • Geode Capital Management sold 13,684 AN2 Therapeutics shares in Q3 2026, an estimated $72.5K.
  • AN2 Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3001 holding.
  • Geode Capital Management first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 18 quarters since.
  • Geode Capital Management's AN2 Therapeutics position peaked at $3.66M in Q4 2023.
  • 51 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.